1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,250 | 7,500 | 10:39 | |
| 7,250 | 7,500 | 10:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | HENGRUI PHARMA (01276): NOTICE OF BOARD MEETING | 2 | HKEx | ||
| Mi | HENGRUI PHARMA (01276): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 26.03. | Jiangsu Hengrui Medicine Co., Ltd Full Year Profit Climbs | 1 | RTTNews | ||
| 26.03. | Jiangsu Hengrui Pharmaceuticals Co.Ltd Bottom Line Climbs In Full Year | - | RTTNews | ||
| JIANGSU HENGRUI PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 26.03. | Hengrui Pharma Announces Strong 2025 Annual Results | 306 | PR Newswire | SHANGHAI, March 25, 2026 /PRNewswire/ -- On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled... ► Artikel lesen | |
| 25.03. | HENGRUI PHARMA (01276): FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2025 | 3 | HKEx | ||
| 25.03. | HENGRUI PHARMA (01276): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT | 1 | HKEx | ||
| 25.03. | HENGRUI PHARMA (01276): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 25.03. | HENGRUI PHARMA (01276): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 2 | HKEx | ||
| 25.03. | Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Hengrui Pharma Announces Strong 2025 Annual Results | 308 | JCN Newswire | HONG KONG, Mar 25, 2026 - (ACN Newswire) - On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation... ► Artikel lesen | |
| 25.03. | HENGRUI PHARMA (01276): CONNECTED TRANSACTION - CAPITAL INCREASE AGREEMENT | 5 | HKEx | ||
| 25.03. | HENGRUI PHARMA (01276): FORM OF PROXY FOR USE AT THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 25.03. | HENGRUI PHARMA (01276): NOTICE OF 2025 ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 25.03. | HENGRUI PHARMA (01276): 2025 ANNUAL GENERAL MEETING CIRCULAR | 1 | HKEx | ||
| 24.03. | HK Govt Appoints 4 New Members to Chief Executive's Council of Advisers, Including Chairmen of HENGRUI PHARMA, BIREN TECH, BIDU-SW | 20 | AASTOCKS | ||
| 13.03. | HENGRUI PHARMA (01276): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL FOR DRUG REGISTRATION | - | HKEx | ||
| 11.03. | HENGRUI PHARMA (01276): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 05.03. | Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal | 45 | FierceBiotech | ||
| 02.03. | HENGRUI PHARMA (01276): (1) PROPOSED ELECTION OF NEW SESSION OF THE BOARD, (2) RETIREMENT AND PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, ... | - | HKEx | ||
| 26.02. | HENGRUI PHARMA (01276): NEXT DAY DISCLOSURE RETURN | 1 | HKEx |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 40,310 | -0,35 % | Dax zeigt zum Wochenausklang Comeback-Qualitäten: Bayer - Aktie vertagt Entscheidung; könnte aber bald durchstarten | Was für eine Handelswoche! Einmal mehr bewegte US-Präsident Trump die Aktienmärkte, doch nicht nur die. Signale der Entspannung wurden von den Aktienindizes und Edelmetallen unter der Woche mit Kurs-... ► Artikel lesen | |
| DERMAPHARM | 43,600 | +1,28 % | EQS-PVR: Dermapharm Holding SE: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG | EQS Stimmrechtsmitteilung: Dermapharm Holding SE
Dermapharm Holding SE: Veröffentlichung über Erwerb oder Veräußerung eigener Aktien nach § 40 Abs. 1 Satz 2 WpHG
07.04.2026... ► Artikel lesen | |
| ZOETIS | 102,35 | -0,20 % | Zoetis Inc. to Acquire Animal Genomics Business from Neogen, Accelerating Precision Animal Health Innovation | Acquisition strengthens Zoetis' leadership in Precision Animal Health by integrating Neogen's global genomics capabilities, expanding predictive insights and individualized care worldwide
PARSIPPANY... ► Artikel lesen | |
| SINOPHARM | 2,264 | -0,70 % | Reed Sinopharm Exhibitions (RSE): PCHi 2026: World's Largest Cosmetics Ingredients Exhibition Opens in Hangzhou | 860+ exhibitors from 26 countries and regions across 70,000 sqmClose to 50 new product launches, including global and China debuts295 product submissions and 19 engineer nominations for the... ► Artikel lesen | |
| CSPC PHARMA | 0,998 | -0,63 % | CSPC PHARMA (01093): UPDATE ANNOUNCEMENT - CONNECTED TRANSACTION IN RELATION TO THE DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY | ||
| FILANA THERAPEUTICS | 1,426 | 0,00 % | Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. | New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading... ► Artikel lesen | |
| CANTOURAGE GROUP | 4,610 | 0,00 % | Original-Research: Cantourage Group SE (von NuWays AG): BUY | Original-Research: Cantourage Group SE - from NuWays AG
18.03.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,330 | +0,46 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| DAIICHI SANKYO | 14,802 | -3,04 % | Imagene AI Announces Collaboration with Daiichi Sankyo to Advance Multimodal Biomarker Discovery in Oncology | Collaboration leverages Imagene's OI Suite, powered by CanvOI and a large-scale multimodal real-world data lake, alongside Composite Continuous Scoring to strengthen biomarker-driven decisions. MIAMI... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 63,56 | -1,44 % | RBC Capital startet Coverage für BridgeBio Pharma mit "Outperform" und Kursziel 100 US-Dollar | ||
| HIKMA PHARMACEUTICALS | 15,360 | +1,45 % | Hikma Pharmaceutical - Director/PDMR Shareholding | ||
| ORION | 73,60 | +1,31 % | Orion Oyj: Orion publishes Interim Report for January-March 2026 and holds a webcast on 23 April 2026 | ||
| ALK-ABELLO | 28,000 | +0,65 % | ALK Abello: Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff | ||
| ACLARIS THERAPEUTICS | 3,452 | -1,15 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis | - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| OTSUKA HOLDINGS | 60,00 | +1,69 % | Biodexa Pharmaceuticals PLC: Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer | MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST)Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 2026... ► Artikel lesen |
Das Unternehmen JIANGSU HENGRUI PHARMACEUTICALS CO LTD kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 7,250 Euro und damit +1,40 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JIANGSU HENGRUI PHARMACEUTICALS CO LTD finden Sie auf Wallstreet Online.